MENU
IMTX
AS OF
Dec 24 closing price
Price
$10.37
Change
+$0.15 (+1.47%)
Capitalization
1.39B
90 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
IMTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Immatics (IMTX) Ownership - Who owns Immatics?

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more

#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.39B
P/E Ratio
27.61
Total Cash
430.84M
Projected Growth
N/A
Total Debt
16.38M
Revenue
84.76M
Risk (Beta)
1.54
Dividend Yield
N/A
Total Cash/Share
3.21
Total Debt/Equity
N/A
Revenue/Share
0.83 USD as % of share price

Fundamentals

IMTX
Capitalization
1.39B
P/E Ratio
27.61
Risk (Beta)
1.54
Dividend Yield
N/A
Total Cash
431M
Total Cash/Share
3.21
Total Debt
16.4M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.83%
Revenue
84.8M
ROE
N/A
Book Value
417M
P/B Ratio
2.83
Cash Flow
N/A
Earnings
-0.93
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
1.22M
Current Ratio
7.36
Current Revenue Per Employee
12262.41
Dividends Per Share - Security
N/A
EBITDA
-106.34M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-21.13
Shares Held By Institutions
1.06B
Shares Outstanding - Current
134M
Total Liabilities
102M
Total Volume MTD
N/A
Value
-1
Gain YTD
45.851
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
IMTX
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMTX showed earnings on November 17, 2025. You can read more about the earnings report here.
View AI-Driven Trading for IMTX
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com